Serum nm23-H1 protein as a prognostic factor for indolent non-Hodgkin's lymphoma

Leukemia

Volumn 15, Issue 5, 2001, Pages 832-839

  Niitsu, N ^a,b   Okamoto, M ^c   Okabe Kado, J ^b   Takagi, T ^d   Yoshida, T ^e   Aoki, S ^f   Honma, Y ^b   Hirano, M ^c  

^a KITASATO UNIVERSITY   (Japan)

^b SAITAMA CANCER CENTER   (Japan)

^c FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d CHIBA CANCER CENTER   (Japan)

^e TOYAMA PREFECTURAL CENTRAL HOSPITAL   (Japan)

^f NIIGATA UNIVERSITY   (Japan)

Author keywords

Indolent lymphoma; nm23 H1 protein; Prognostic factor

Indexed keywords

DIFFERENTIATION INDUCING FACTOR; NUCLEOSIDE DIPHOSPHATE KINASE A; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE ACTIVITY; FEMALE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; SURVIVAL RATE;

EID: 0035000749     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2402105     Document Type: Article

References (32)

1. Follicular lymphoma: Assessment of prognostic factors in 127 patients followed for 10 years
2. A predictive model for aggressive non-Hodgkin's lymphoma: The International NHL Prognostic Factors Project
3. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy
4. Multicenter phase II study of iodine-131 tositumomab for chemotherapy- relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas
5. Autologous bone marrow transplantation in poor-prognosis intermediate-grade and high-grade B-cell non-Hodgkin's lymphoma in first remission: A pilot study
6. Identity of differentiation inhibiting factor for mouse myeloid leukemia cells with NM23/nucleoside diphosphate kinase
7. A new function of Nm23/NDP kinase as a differentiation inhibitory factor, which does not require its kinase activity
8. Variability of nm23-H1/NDPK-A expression in human lymphomas and its relation to tumor aggressiveness
9. Prognostic implications of the differentiation inhibitory factor nm23-H1 protein in the plasma of aggressive non-Hodgkin's lymphoma
10. Plasma levels of the differentiation inhibitory factor nm23-H1 protein and their clinical implication in acute myelogenous leukemia
11. A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma study group
12. Report of the committee on Hodgkin's disease staging classification
13. High serum interleukin-2 receptor levels are related to advanced disease and a poor outcome in childhood non-Hodgkin's lymphoma
14. Nonparametric estimation from incomplete observations
15. Individual comparisons by ranking methods
16. Evaluation of survival data and two new rank order statistics arising in its consideration
17. Regression models and life tables
18. How should prognostic factors influence therapy in follicular lymphoma?
19. The natural history of untreated low-grade non-Hodgkin's lymphomas
20. IDEC-C2B8 (Rituximab) antibody CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma
21. Applicability of the international index for aggressive lymphomas to patients with low-grade lymphoma
22. Follicular lymphoma: Prognotic factors for response and survival
23. Prognostic indicators in centroblastic-centrocytic lymphoma
24. Prognostic value of serum beta2-microglobulin in low-grade lymphoma
25. Identification of prognostic groups in follicular lymphoma
26. Evidence for a novel gene associated with low tumor metastatic potential
27. Nucleoside diphosphate kinase from human erythrocytes
28. nm23: Unraveling its biological function in cell differentiation
29. Differentiation inhibitory factor nm23 as a new prognostic factor in acute monocytic leukemia
30. Differentiation inhibitory factor Nm23 as a prognostic factor for acute myeloid leukemia
31. Prognostic value of serum beta-2 microglobulin in low-grade lymphoma
32. High serum interleukin-6 levels correlate with a shorter failure-free survival in indolent lymphoma